KR940008695A - 안티트롬빈 iii제제 - Google Patents

안티트롬빈 iii제제 Download PDF

Info

Publication number
KR940008695A
KR940008695A KR1019930020297A KR930020297A KR940008695A KR 940008695 A KR940008695 A KR 940008695A KR 1019930020297 A KR1019930020297 A KR 1019930020297A KR 930020297 A KR930020297 A KR 930020297A KR 940008695 A KR940008695 A KR 940008695A
Authority
KR
South Korea
Prior art keywords
antithrombin iii
powder
solvent
alkyl ester
polyoxyethylene glycol
Prior art date
Application number
KR1019930020297A
Other languages
English (en)
Other versions
KR100264707B1 (ko
Inventor
도시노부 아오야마
Original Assignee
가토 에이치.
훽스트 제펜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17402131&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR940008695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 가토 에이치., 훽스트 제펜 리미티드 filed Critical 가토 에이치.
Publication of KR940008695A publication Critical patent/KR940008695A/ko
Application granted granted Critical
Publication of KR100264707B1 publication Critical patent/KR100264707B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 폴리옥시에틸렌 글리콜 소르비탄 알킬 에스테르를 안티트롬빈 Ⅲ의 동결건조된 분말 및 이 분말에 대한 용매중 하나 또는 둘다에 가함을 특징으로 하여, 안티트롬빈 Ⅲ의 동결건조된 분말 및 폴리옥시에틸렌 글리콜 소르비탄 알킬 에스테르외에도 안티트롬빈 III의 동결건조된 분말이 놓여있는 용기 및 이 분말에 대한 용매로 구성된 키티를 포함한 안티트롬빈 Ⅲ를 기술한다. 본 제제는 이의 활성을 보유하면서 높은 용해도를 갖는다.

Description

안티트롬빈 Ⅲ제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 안티트롬빈 Ⅲ의 동결건조된 분말 및 폴리옥시에틸렌 글리콜 소르비탄 알킬 에스테를 포함한 안티트롬빈 Ⅲ제제.
  2. 제1항에 있어서, 폴리옥시에틸렌 글리콜 소르비탄 알킬 에스테르가 트윈(Tween)20, 40, 60 또는 80인 안티트롬빈 Ⅲ제제.
  3. 제1항 또는 제2항에 있어서, 폴리옥시에틸렌 글리콜 소르비탄 알킬 에스테르를 안티트롬빈 Ⅲ 중량의 0.04내지 20% 양으로 사용하는 안티트롬빈 Ⅲ제제.
  4. 폴리옥시에틸렌 글리콜 소르비탄 알킬 에스테르를 안티트롬빈 Ⅲ의 동결건조된 분말 및 이 분말에 대한 용매중 하나 또는 둘다에 가함을 특징으로 하는, 안티트롬빈 Ⅲ의 동결조건된 분말이 놓여 있는 용기 및 이 분말에 대한 용매가 놓여 있는 용기를 포함하는 안티트롬빈 Ⅲ제제의 키트.
  5. 제4항에 있어서, 용매가 주사용 증류수인 키트.
  6. 제4항에 있어서, 분말 및 용매에 대한 용기가 바이알인 키트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930020297A 1992-10-02 1993-10-02 안티트롬빈 iii 제제 KR100264707B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26436492A JP3494667B2 (ja) 1992-10-02 1992-10-02 アンチトロンビンｉｉｉ製剤
JP92-264364 1992-10-02

Publications (2)

Publication Number Publication Date
KR940008695A true KR940008695A (ko) 1994-05-16
KR100264707B1 KR100264707B1 (ko) 2000-09-01

Family

ID=17402131

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930020297A KR100264707B1 (ko) 1992-10-02 1993-10-02 안티트롬빈 iii 제제

Country Status (12)

Country Link
US (1) US5385890A (ko)
EP (1) EP0590531B1 (ko)
JP (1) JP3494667B2 (ko)
KR (1) KR100264707B1 (ko)
AT (1) ATE188385T1 (ko)
AU (1) AU672430B2 (ko)
CA (1) CA2107516C (ko)
DE (1) DE69327498T2 (ko)
DK (1) DK0590531T3 (ko)
ES (1) ES2141123T3 (ko)
GR (1) GR3032580T3 (ko)
PT (1) PT590531E (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022471A1 (en) * 1993-04-05 1994-10-13 The Green Cross Corporation Liquid antithrombin iii preparation and method of stabilizing the same
AT405905B (de) * 1997-03-25 1999-12-27 Immuno Ag Neue verwendung von antithrombin iii
US6518406B1 (en) * 1999-06-23 2003-02-11 Octapharma Ag Method for purification of proteins
CN114813287A (zh) * 2022-06-29 2022-07-29 深圳市帝迈生物技术有限公司 一种用于肝素抗凝检测的校准品及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS597693B2 (ja) * 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4613501A (en) * 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US5319072A (en) * 1992-01-10 1994-06-07 Alpha Therapeutic Corporation Human antithrombin-III preparation

Also Published As

Publication number Publication date
AU4872893A (en) 1994-04-14
ATE188385T1 (de) 2000-01-15
PT590531E (pt) 2000-05-31
EP0590531B1 (en) 2000-01-05
ES2141123T3 (es) 2000-03-16
JP3494667B2 (ja) 2004-02-09
DE69327498T2 (de) 2000-06-08
US5385890A (en) 1995-01-31
CA2107516C (en) 2004-12-07
DK0590531T3 (da) 2000-06-13
DE69327498D1 (de) 2000-02-10
CA2107516A1 (en) 1994-04-03
JPH06116167A (ja) 1994-04-26
AU672430B2 (en) 1996-10-03
GR3032580T3 (en) 2000-05-31
EP0590531A1 (en) 1994-04-06
KR100264707B1 (ko) 2000-09-01

Similar Documents

Publication Publication Date Title
NO307205B1 (no) Preparater basert på virkestoffer fra taxanklassen samt perfusjonspreparater inneholdende disse
ES2119996T3 (es) Composicion inyectable que comprende faclitaxel.
ES2102157T3 (es) Emulsion agua en aceite para uso cosmetico o farmaceutico.
ES2053929T3 (es) Composiciones anti-transpirantes.
GR3035067T3 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins.
IT8721213A0 (it) Idroformilazione con l'uso di leganti costituiti da fosfina organico solubile di bassa volatilita'.
ATE141498T1 (de) Sonnenschutzmittel
AU560436B2 (en) 5-substituted 1,2,4,-oxadiazole derivatives
KR840002650A (ko) 유비데카레논을 함유하는 약학적 조성물
AU591780B2 (en) Benzo{b}thiophene- and benzo{b}furancarboxamide derivatives their preparation, and pharmaceutical compositions containing them
DE3382637D1 (de) Eine lipidloesliche substanz enthaltende waessrige fluessigkeit.
EP0358284A3 (en) Derivatized alkanolamines as cardiovascular agents
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
KR890007754A (ko) 항체류의 안정화
ES2041249T3 (es) Preparaciones liquidas de 1,2-benzoisotiazolin-3-ona, su obtencion y empleo.
AR246871A1 (es) Composicion desodorante de ambientes.
KR940008695A (ko) 안티트롬빈 iii제제
KR890006639A (ko) 벤조티아진 디옥사이드 유도체
SE8100005L (sv) Vattenhaltiga kompositioner innehallande stabiliserade enzymer
KR860003825A (ko) 안정한 현탁액 제조용 고체 약물제형의 제조방법
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
BR7902860A (pt) Novos derivados de 1,5-dimetil biciclo(3,2,1)octano,preparacao destes compostos,e seu uso com compostos de perfume
KR970070134A (ko) 분산 염료의 저장안정성 액체 제형 및 그의 제조방법
KR910700047A (ko) 쇼듐 크로모글리케이트를 함유하는 에어로솔 조성물
AU2169088A (en) Thionophosphonates

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060525

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee